Business
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Daniel B. Gilmer, Ph.D. has joined the Company's Board of Directors, effective April 24, 2026. Dr. Gilmer has served as Senior Director, Commercial Quality U.S. Team Lead at Pfizer
About this update from Armata Pharmaceuticals, Inc.
[{"type":"text","content":"LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Daniel B. Gilmer, Ph.D. has joined the Company's Board of Directors, effective April 24, 2026. Dr. Gilmer has served as Senior Director, Commercial Quality U.S. Team Lead at Pfizer Inc. ("Pfizer") since February 2025.","length":615,"tagName":"p"},{"type":"image","alt":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":233,"url":"https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TDyYNi5HXQc0YIMWA0R4MQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQxMQ--/https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d","width":400,"height":233}},"href":"https://mma.prnewswire.com/media/884786/Armata_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""I am pleased to welcome Daniel to our Board and look forward to leveraging his many years of experience spanning scientific discovery, commercial strategy, and patient access," stated Robin C. Kramer, Chair of Armata's Board of Directors. "Daniel has discovered and helped advance first-in-class anti-infective candidates and has played pivotal roles in the launch and commercialization of breakthrough therapies and diagnostics, including leading the U.S. launch of PAXLOVIDTM. His perspectives on antimicrobial resistance, diagnostics, and access to innovation will be invaluable as we continue to advance our phage-based pipeline to commercialization."","length":680,"tagName":"p"},{"type":"text","content":""I am very excited to join Armata's Board and work alongside my fellow Directors and the leadership team to help the Company achieve its clinical and commercial goals," stated Dr. Gilmer. "Armata is developing precisely targeted bacteriop...